Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Increases By 1,180.7%

Posted by Casey Walker on Feb 13th, 2025

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, a growth of 1,180.7% from the January 15th total of 211,600 shares. Based on an average daily trading volume, of 17,180,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 25.5% of the company’s shares are sold short.

Institutional Investors Weigh In On Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP bought a new position in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals as of its most recent SEC filing. 17.24% of the stock is owned by institutional investors.

Hepion Pharmaceuticals Stock Up 0.8 %

HEPA opened at $0.20 on Thursday. Hepion Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $3.49. The company has a market capitalization of $1.40 million, a P/E ratio of -0.05 and a beta of 1.65. The stock’s fifty day moving average is $0.42 and its two-hundred day moving average is $0.59.

About Hepion Pharmaceuticals

(Get Free Report)

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.